Efficacy of ivabradine in treating patients with chronic heart failure complicated with arrhythmia
LI Ying
LIU Xiaona
WANG Linlin
LI Minghui
Abstract：Objective To analyze the efficacy of ivabradine in the treatment of patients with chronic heart failure(CHF)complicated with arrhythmia.Methods A prospective randomized controlled trial was conducted.A total of 118 patients with CHF complicated with arrhythmia treated at the Second People's Hospital of Hengshui from January 2022 to January 2025 were selected and divided into the ivabradine group and the control group in equal proportions using a simple randomization method(SAS 9.4 random sequence).The control group was treated with metoprolol succinate,while the ivabradine group was given ivabradine in addition to this regimen.The course of treatment was 12 weeks.Cardiac function indicators,heart rate variability(HRV)indicators,and vascular endothelial function indicators were compared before and after treatment,and the incidence rates of drug-related adverse reactions were compared after treatment.Results After 12 weeks of treatment,left ventricular ejection fraction and flow-mediated dilation in the ivabradine group((50.34±2.26)%and(9.42±1.59)%)were significantly higher than(47.97±2.39)%and(8.70±1.74)%in the control group(t=5.534,2.346,both P<0.05),while left ventricular end-diastolic diam-eter and left ventricular posterior wall thickness in the ivabradine group((54.71±4.26)and(8.26±1.63)mm)were significantly lower than(58.20±4.59)and(9.04±1.70)mm in the control group(t=4.280,2.544,both P<0.05).No statistical significance in standard deviation of the NN intervals(SDNN)was found in the control group before and after treatment(P>0.05).After treat-ment,the SDNN and root mean square of successive differences in the ivabradine group((110.28±14.19)and(29.28±5.60)ms)were significantly higher than(102.03±12.48)and(25.90±5.52)ms in the control group,while the low frequency/high fre-quency ratio in the ivabradine group(2.0(1.7,2.6))was significantly lower than(2.3(1.9,3.0))in the control group(t=3.353,3.301,Z=3.384,all P<0.05).After treatment,the serum levels of endothelin-1,von Willebrand factor in the ivabradine group((6.73±1.14),(6.92±1.04)ng/mL)were significantly lower than those in the control group((7.35±1.32),(7.57±1.18)ng/mL)(t=2.730,3.174,both P<0.05).There was no statistical difference in the incidence of adverse reactions between the ivabradine group(11.83%(7/59))and the control group(8.45%(5/59))(χ2=0.371,P=0.542).Conclusion The application of ivabradine in patients with CHF complicated by arrhythmia can improve cardiac function and HRV indicators.
Keywords：chronic heart failurearrhythmiaivabradinemetoprololcardiac functionheart rate variability
Publication Date：2026-03-25
Online Publishing Date：2026-04-07(First online date of this platform, not the publication date of the document)
Pages：5( 368-372 )